Oragenics Inc financial data

Symbol
OGEN on NYSE
Industry
Pharmaceutical Preparations
Location
1990 Main Street, Suite 750, Sarasota, FL
State of incorporation
FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 514 % -57.9%
Return On Equity -573 % -447%
Return On Assets -409 % -346%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.58M shares +120%
Common Stock, Shares, Outstanding 5.58M shares +176%
Entity Public Float 6.7M USD -83.9%
Common Stock, Value, Issued 5.58K USD +176%
Weighted Average Number of Shares Outstanding, Basic 4.53M shares +124%
Weighted Average Number of Shares Outstanding, Diluted 4.53M shares +124%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 37.7K USD -71.4%
Research and Development Expense 13.4M USD +70.1%
General and Administrative Expense 6.28M USD +40.6%
Operating Income (Loss) -19.7M USD -60.9%
Nonoperating Income (Expense) 141K USD -35.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19.5M USD -62.6%
Net Income (Loss) Attributable to Parent -19.5M USD -62.6%
Earnings Per Share, Basic -7.47 USD/shares -26.8%
Earnings Per Share, Diluted -7.47 USD/shares +66.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.35M USD -79.2%
Assets, Current 1.62M USD -80%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 9.81K USD -97.2%
Assets 2.71M USD -68%
Accrued Liabilities, Current 181K USD -45.9%
Liabilities, Current 1.8M USD +12.6%
Operating Lease, Liability, Noncurrent 65.8K USD -69.7%
Liabilities 1.38M USD
Retained Earnings (Accumulated Deficit) -211M USD -10.2%
Stockholders' Equity Attributable to Parent 1.33M USD -81.7%
Liabilities and Equity 2.71M USD -68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.06M USD -45.3%
Net Cash Provided by (Used in) Financing Activities 1.65M USD
Net Cash Provided by (Used in) Investing Activities -75K USD
Common Stock, Shares Authorized 350M shares +8300%
Common Stock, Shares, Issued 5.58M shares +176%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.41M USD +37.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.09K USD +112%
Deferred Tax Assets, Valuation Allowance 47M USD +14.1%
Deferred Tax Assets, Gross 47M USD +14.1%
Operating Lease, Liability 9.81K USD -97.3%
Payments to Acquire Property, Plant, and Equipment 87K USD
Lessee, Operating Lease, Liability, to be Paid 9.89K USD -97.4%
Property, Plant and Equipment, Gross 1.48M USD
Operating Lease, Liability, Current 9.81K USD -95.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 157K USD +6.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.89K USD -95.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 381 USD -98.4%
Deferred Tax Assets, Operating Loss Carryforwards 39.8M USD +5.56%
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 4.17M USD -13.8%
Operating Lease, Payments 59.3K USD +1.26%
Additional Paid in Capital 211M USD +6.89%
Share-based Payment Arrangement, Expense 58.2K USD -8.5%
Interest Expense 34.3K USD +126%